Prophylaxis for Cancer-Associated Venous Thromboembolic Disease
VTE is common among patients with cancer and represents an appreciable risk, with associated morbidity and mortality. Accurate VTE risk assessment is important in identifying appropriate candidates for VTE prophylaxis and at times can prevent unnecessary use of anticoagulants. Selecting a suitable regimen in these patients requires guidance from physicians with experience treating various oncology subpopulations.
  • Venous Thromboembolic Disease
  • Recorded Webcast
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation